Currently, Wilms’ tumor 1 (WT1), preferentially expressed antigen in melanoma (PRAME), and minor histocompatibility antigens (MiHA) have been the only AML antigens targeted using TCR-T cells in a clinical setting. Here, WT1 is linked to melanoma.